Sign Up for a Free Account
  • Updated 04.15.2021
  • Released 08.27.2011
  • Expires For CME 04.15.2024

Endovascular treatment of acute ischemic stroke

Introduction

Overview

Powerful new data from multiple randomized-controlled trials published in 2015 proved that mechanical thrombectomy with stent retrievers is superior to standard medical care in the treatment of carefully selected patients with acute ischemic stroke caused by large vessel occlusion in the proximal anterior circulation. Further studies in 2018 demonstrated the efficacy of mechanical thrombectomy in select patients up to 24 hours after onset of symptoms. It has been shown that direct aspiration can be used as an alternative to stent retrievers in acute ischemic stroke.

Acute ischemic stroke affects nearly 800,000 patients in the United States annually and is one of the leading causes of morbidity and mortality (07). Intracranial large vessel occlusion, most commonly involving the proximal middle cerebral artery or intracranial internal carotid artery, occurs in approximately 30% of acute ischemic strokes (32). Until recently, the only proven therapy for acute ischemic stroke was the administration of intravenous recombinant tissue plasminogen activator (IV-rtPA) within 4.5 hours of symptom onset (42; 22; 15). Although timely administration of IV-rtPA improves functional independence at 90 days, it does not reduce mortality versus placebo (42; 22; 15). Additionally, recanalization rates of acute ischemic stroke with large vessel occlusion treated with IV-rtPA remain extremely low (09; 24; 07). This is an important concept because large vessel occlusion recanalization rates are closely associated with good outcomes and reduced mortality (09; 18; 07). Furthermore, several studies have demonstrated a link between failed IV-rtPA recanalization and clot burden, suggesting there is a limit to the efficacy of IV-rtPA in the setting of large vessel occlusion (09; 59; 07). The limitations of IV-rtPA in the setting of large vessel occlusion have led to the emergence and rapid evolution of intraarterial therapies for the treatment of acute ischemic stroke.

Key points

• Acute ischemic stroke is a major cause of morbidity and mortality in the United States and worldwide.

• Until recently, the only FDA-approved treatment for acute ischemic stroke was intravenous rtPA given within 4.5 hours of stroke onset.

• New mechanical thrombectomy techniques, including stent retrievers and direct aspiration, have greatly improved recanalization rates for patients with acute ischemic strokes caused by intracranial large vessel occlusion.

• Multiple randomized, controlled trials demonstrated the efficacy and superiority of mechanical thrombectomy over standard medical care in carefully selected acute ischemic stroke patients.

• Recent major studies demonstrated the efficacy of medical thrombectomy over standard medical care in carefully selected patients up to 24 hours after stroke onset.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com